Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials2013; 347 doi: http://dx.doi.org/10.1136/bmj.f5934 (Published 22 October 2013) Cite this as: 2013;347:f5934
- Viktoria L Gloy, junior researcher1,
- Matthias Briel, assistant professor12,
- Deepak L Bhatt, professor3,
- Sangeeta R Kashyap, associate professor of medicine4,
- Philip R Schauer, medical director, professor of surgery5,
- Geltrude Mingrone, professor6,
- Heiner C Bucher, director1,
- Alain J Nordmann, associate professor1
- 1Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Hebelstrasse 10, CH-4031 Basel, Switzerland
- 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
- 3VA Boston Healthcare System, Brigham and Women’s Hospital, and Harvard Medical School, Boston, USA
- 4Endocrinology Institute, Cleveland Clinic, Cleveland, USA
- 5Bariatric & Metabolic Institute, Cleveland Clinic, Cleveland, USA
- 6Department of Internal Medicine, Università Cattolica S. Cuore, Rome, Italy
- Correspondence to: V L Gloy
- Accepted 3 September 2013
Objective To quantify the overall effects of bariatric surgery compared with non-surgical treatment for obesity.
Design Systematic review and meta-analysis based on a random effects model.
Data sources Searches of Medline, Embase, and the Cochrane Library from their inception to December 2012 regardless of language or publication status.
Eligibility criteria Eligible studies were randomised controlled trials with ≥6 months of follow-up that included individuals with a body mass index ≥30, compared current bariatric surgery techniques with non-surgical treatment, and reported on body weight, cardiovascular risk factors, quality of life, or adverse events.
Results The meta-analysis included 11 studies with 796 individuals (range of mean body mass index at baseline 30-52). Individuals allocated to bariatric surgery lost more body weight (mean difference −26 kg (95% confidence interval −31 to −21)) compared with non-surgical treatment, had a higher remission rate of type 2 diabetes (relative risk 22.1 (3.2 to 154.3) in a complete case analysis; 5.3 (1.8 to 15.8) in a conservative analysis assuming diabetes remission in all non-surgically treated individuals with missing data) and metabolic syndrome (relative risk 2.4 (1.6 to 3.6) in complete case analysis; 1.5 (0.9 to 2.3) in conservative analysis), greater improvements in quality of life and reductions in medicine use (no pooled data). Plasma triglyceride concentrations decreased more (mean difference −0.7 mmol/L (−1.0 to −0.4) and high density lipoprotein cholesterol concentrations increased more (mean difference 0.21 mmol/L (0.1 to 0.3)). Changes in blood pressure and total or low density lipoprotein cholesterol concentrations were not significantly different. There were no cardiovascular events or deaths reported after bariatric surgery. The most common adverse events after bariatric surgery were iron deficiency anaemia (15% of individuals undergoing malabsorptive bariatric surgery) and reoperations (8%).
Conclusions Compared with non-surgical treatment of obesity, bariatric surgery leads to greater body weight loss and higher remission rates of type 2 diabetes and metabolic syndrome. However, results are limited to two years of follow-up and based on a small number of studies and individuals.
Systematic review registration PROSPERO CRD42012003317 (www.crd.york.ac.uk/PROSPERO).
Obesity is one of the greatest public health problems in industrialised countries.1 2 In the US, UK, and Australia, for instance, the prevalence of obesity (body mass index (weight (kg)/(height (m)2) >30) has more than doubled in the past 25 years.2 Currently, 67% of the US population is either overweight or obese, and in most European countries the prevalence ranges between 40% and 50%.3 Obesity is associated with an increased risk for type 2 diabetes, hypertension, dyslipidaemia, cardiovascular diseases, musculoskeletal disorders (such as osteoarthritis), certain types of cancer, and mortality.4 This entails huge healthcare costs due to obesity.5
Treatment options for obesity include non-surgical treatment and bariatric surgery. The non-surgical treatment is usually a multicomponent approach comprising behavioural therapy, dietary changes with the main aim of reducing energy intake, increasing physical activity, and various pharmacotherapies.6 The most commonly used bariatric surgery techniques are Roux-en-Y gastric bypass, sleeve gastrectomy, and laparoscopic adjustable gastric banding.7 8 9 Current guidelines recommend evaluation of bariatric surgery for individuals with a body mass index >40 or >35 with serious comorbidities related to obesity.8 10 A Cochrane review from 2009 suggested greater body weight loss, improvement in the control of comorbidities, and better quality of life in obese patients who underwent bariatric surgery compared with non-surgical treatment for obesity.11 However, the review included only a qualitative summary of three randomised controlled trials.11 12 Since then several further randomised controlled trials have been completed. The present systematic review and meta-analysis aims at comprehensively summarising and quantifying the effects of bariatric surgery compared with non-surgical treatment in randomised controlled trials on weight loss, cardiovascular risk factors, adverse events, and quality of life in individuals with a body mass index ≥30.
Studies were eligible if they were randomised controlled trials (≥6 months’ follow-up); included individuals with a body mass index ≥30; investigated currently used laparoscopic or open bariatric surgery techniques (Roux-en-Y gastric bypass, adjustable gastric banding, sleeve gastrectomy, biliopancreatic diversion, or biliopancreatic diversion with duodenal switch); investigated as comparator non-surgical treatment for obesity (diet, weight reducing drugs, behavioural therapy, or any combination thereof); and reported changes in body weight; body fat mass; fat-free mass; waist circumference; blood pressure; fasting levels of plasma total cholesterol, high density and low density lipoproteins, triglycerides, glycated haemoglobin HbA1c, and glucose; quality of life from baseline to the end of follow-up; remission of type 2 diabetes, metabolic syndrome, or hypertension; reduction in the use of antihypertensive, antidiabetic, or lipid lowering drugs; and adverse events.
Information sources and searches
We aimed to identify all relevant studies regardless of language or publication status. We searched Medline (via Pubmed), Embase, and the Cochrane Library from their inception to June 2013 (for search strategies see appendix tables 1 and 2 on bmj.com). We also searched trial registries of ongoing trials (appendix table 3). Additionally, we contacted authors to obtain additional data.
Two reviewers independently screened retrieved database files and the full text of potentially eligible studies for relevance. Disagreement was resolved by consensus.
Data collection and risk of bias assessment
Two reviewers abstracted data independently into a pilot tested, data abstraction form on general study characteristics, baseline characteristics of individuals, outcomes mentioned above, and assessed risk of bias for each included study at the level of selected outcomes.13 We assessed publication bias by creating a funnel plot for the mean differences in body weight change.14 Disagreement was resolved by consensus.
Data synthesis and analysis
Relative risks (with 95% confidence intervals) were calculated for dichotomous data, and mean differences were calculated for continuous data. Statistical analyses were performed using RevMan 5.1. Outcome measures were quantitatively summarised, if possible, using a random effects model. For some studies the mean change from baseline to end of follow-up was calculated.
Missing standard deviations were derived from other statistics, such as P values or confidence intervals if needed.15 When a P value was reported as, for example, P≤0.001, P=0.001 was assumed.13 Heterogeneity among combined study results was assessed by Cochran’s Q test and by the degree of inconsistency (I2).13 Furthermore, subgroup and sensitivity analyses were performed.
In order to investigate the influence of missing data on the pooled effect sizes for diabetes and metabolic syndrome remission, we conducted both a complete case and a conservative case scenario analysis. In the conservative case scenario, we treated all patients with missing data in the non-surgical treatment group as if they achieved remission and those in the bariatric surgery group as if they did not. The terms remission of type 2 diabetes or metabolic syndrome were used as defined by study authors (appendix table 4).
The study selection process is summarised in figure 1⇓. From a total of 1988 records, 11 studies (n=796) were eligible and included in the meta-analysis. A list of included studies with the corresponding publications, and a table summarising ongoing trials (n=18) is provided in appendix tables 3 and 5. Additional data or information for risk of bias assessment were obtained for the studies Mingrone 2012,16 Mingrone 2002,17 Schauer 2012,18 Ikramuddin 2013,19 and Reis 201020 by contacting the study authors. Standard deviations were derived from the 95% confidence intervals for O’Brien 201021 and Dixon 2012.22 We imputed standard deviations for Mingrone 2002,17 O’Brien 2006,23 and Liang 201324 by taking the median standard deviation of the respective groups of the other studies, because no other statistic was available.
General study characteristics
The 11 studies included were conducted in Australia (4), Italy (2), Denmark (1), US (1), China (1), Brazil (1), and in the US and Taiwan (1) (appendix table 6). Five studies included only individuals with type 2 diabetes,17 18 19 24 25 three studies included only individuals who had made serious attempts at weight loss before,21 22 23 and one study included only individuals with obstructive sleep apnoea.22 Bariatric surgery was compared with non-surgical treatment, which generally comprised alterations in dietary intake, physical activity, behavioural or lifestyle modification, and pharmacotherapy. Study groups are described in appendix table 7. Only four studies17 19 21 22 quantitatively reported restrictions in energy intake. In four studies18 19 22 25 the same treatment for the non-surgical group was also offered to the surgical groups, and in one study an extensive weight loss programme was applied for four months before bariatric surgery.20 One study had a follow-up of 40 weeks,26 four studies had a follow-up of one year,17 18 19 24 and all other studies had a follow-up of two years. The studies comprised two three-arm studies and nine two-arm studies, with five of them evaluating the effects of laparoscopic adjustable gastric banding,21 22 23 25 26 five evaluating Roux-en-Y gastric bypass,16 18 19 20 24 one evaluating sleeve gastrectomy,18 and two evaluating biliopancreatic diversion.16 17 Individuals’ baseline characteristics are presented in table 1⇓. One study21 included adolescents (mean age range 16-17 years); the other studies were of adults (mean age range 37-51 years across studies). Mean body mass index ranged from 30 to 52 across studies. One study reported only ranges of body mass index (40-56) and age (40-56 years) at baseline.26
Risk of bias assessment
Results of the risk of bias assessment are presented in tables 2⇓ and 3⇓ and in more detail in appendix table 8. The sequence generation for randomisation was adequate in all studies but one.26 Concealment of group allocation was unclear in five studies.21 22 24 25 26 In all studies, patients and healthcare providers were not blinded. Data collectors, outcome adjudicators, and data analysts were not blinded as far as outcomes relevant to this review are concerned in two studies,18 20 blinded in three studies,16 17 19 and unclear in the remaining six studies. In all studies patients were analysed in the groups to which they were randomised. In four studies not all individuals randomised were finally analysed.16 21 23 24 Across studies, the percentage of individuals not analysed ranged from 3% to 28% in the non-surgical treatment group and from 1% to 14% in the bariatric surgery group.
Missing continuous outcome data were not addressed appropriately (either not addressed at all or use of baseline data carried forward analysis) in four studies.21 23 24 25 Missing data on diabetes remission were addressed in three of four studies reporting on this outcome.16 18 25 However, the reported risk ratio was based on the complete data set. Missing data on metabolic syndrome remission were not addressed in three of five studies.21 23 25
Publication bias was assessed descriptively for the outcome of body weight loss (appendix fig 1). Because of the limited number of studies, publication bias was judged as unclear.
Changes in body weight were pooled for 10 studies; one study24 reported only on body mass index. Individuals after bariatric surgery lost more body weight (mean difference −26 kg (95% confidence interval −31 to −21), P<0.001) than individuals after non-surgical treatment (fig 2⇓). Heterogeneity among studies was high (I2=95%). Excluding studies with ≤1 year of follow-up did not change the effect size (mean difference −27 kg (−36 to −18)) nor the degree of heterogeneity (I2=96%).
Subgroup analyses—Body weight loss was not significantly different between adjustable gastric banding and other bariatric surgery techniques combined (difference of the mean difference −7 kg, P=0.29) (fig 2⇑), nor between adjustable gastric banding and Roux-en-Y gastric bypass (difference of the changes in mean difference −6 kg, P=0.230) (fig 3⇓). Individuals in trials with a mean baseline body mass index ≥40 lost more body weight than individuals in trials with a mean baseline body mass index <40 (difference of the mean difference −13 kg, P<0.001) (appendix fig 2). Body weight loss was not significantly different between surgically treated individuals who additionally received the same treatment as the non-surgical treatment group (difference of the changes in mean difference −6 kg, P=0.24) and individuals after bariatric surgery who received a different accompanying treatment (appendix fig 3). Across all subgroup analyses, statistical heterogeneity remained high.
Changes in waist circumference were available for six studies.18 19 21 22 23 25 Waist circumference decreased more after bariatric surgery than after non-surgical treatment (mean difference −16 cm (−18 to −13), P<0.001). Heterogeneity was moderate (fig 4⇓).
Fat-free mass and fat mass
Changes in fat-free mass and fat mass were pooled for two studies.17 27 Individuals after bariatric surgery lost more fat-free mass (mean difference −5 kg (−11 to −1), P=0.01) and more fat mass (mean difference −18 kg (−31 to −5), P=0.001) than after non-surgical treatment (appendix fig 4A and 4B).
The relative risk of type 2 diabetes remission was pooled for four studies.16 18 24 25 All of them included only individuals with type 2 diabetes at baseline. Different definitions for diabetes remission were used, and one study24 did not report a definition (appendix table 4). Based on the complete case analysis, the relative risk to achieve diabetes remission was 22 times higher (relative risk 22.1 (3.2 to 154.3), P=0.002) compared with non-surgical treatment (fig 5⇓). Heterogeneity was high. Based on the conservative case scenario, the relative risk to achieve diabetes remission was five times higher (relative risk 5.3 (1.8 to 15.8), P=0.003) after bariatric surgery. Heterogeneity was high (appendix fig 5).
Metabolic syndrome remission
The relative risk of metabolic syndrome remission was available for five studies.18 21 23 25 28 All studies included mixed populations of individuals with and without metabolic syndrome (table 1⇑). Three studies used the same definition for metabolic syndrome remission, one definition was adapted to adolescents, and the other study did not report on a definition (appendix table 4). Based on the complete case analysis, the relative risk to achieve metabolic syndrome remission was 2.4 times higher (relative risk 2.4 (1.6 to 3.6), P<0.001) compared with non-surgical treatment. Heterogeneity was moderate (fig 6⇓). Based on the conservative case scenario, there was no significant difference in metabolic syndrome remission between bariatric surgery and non-surgical treatment (relative risk 1.5 (0.9 to 2.3), P=0.12). Heterogeneity was high (appendix fig 6).
This was not addressed by any of the studies.
The mean changes in systolic blood pressure were available for seven studies16 18 19 21 24 25 28 and changes in diastolic blood pressure for six studies.16 18 19 21 25 28 Changes in systolic (mean difference −8.8 mm Hg (−26.2 to 8.5), P=0.32) and diastolic (mean difference −0.4 mm Hg (−2.9 to 2.1), P=0.77) blood pressure were not significantly different between bariatric surgery and non-surgical treatment. Heterogeneity was high for systolic and moderate for diastolic blood pressure (appendix fig 7A and 7B).
The mean changes in triglyceride concentrations were available for eight studies.16 17 18 19 21 24 25 28 Triglycerides decreased more after bariatric surgery (mean difference −0.7 mmol/L (−1.0 to −0.4), P<0.001) than after non-surgical treatment. Heterogeneity was high (fig 7⇓).
The mean changes in total cholesterol concentration were pooled for seven studies.16 17 18 19 24 25 28 Change of cholesterol was not significantly different between bariatric surgery and non-surgical treatment (mean difference −0.4 mmol/L (−0.8 to 0.00), P=0.05). Heterogeneity was high (fig 8⇓).
Changes in high density lipoprotein cholesterol concentration were available for eight studies.16 17 18 19 21 24 25 28 Concentration increased more after bariatric surgery than after non-surgical treatment (mean difference 0.21 mmol/L (0.1 to 0.3), P<0.001). Heterogeneity was high (fig 9⇓).
The mean changes in low density lipoprotein cholesterol concentration were available for five studies.16 17 18 19 24 Changes in concentration were not significantly different between the two groups (mean difference −0.6 mmol/L (−1.2 to −0.01), P=0.06). Heterogeneity was high (fig 10⇓).
Mean changes in fasting glucose levels were available for seven studies.16 17 18 19 21 25 28 Glucose levels decreased more after bariatric surgery than after non-surgical treatment (mean difference −1.5 mmol/L (−2.1 to −0.8), P<0.001). Heterogeneity was high (fig 11⇓. and appendix fig 9). Glucose levels decreased more after Roux-en-Y gastric bypass, sleeve gastrectomy, or biliopancreatic diversion than after adjustable gastric banding (test for subgroup differences P<0.001) for all patients (fig 11⇓) as well as for studies which included patients with diabetes only (appendix fig 8).
Mean changes in glycated haemoglobin HbA1c were pooled for the five studies including only individuals with type 2 diabetes.16 18 19 24 25 HbA1c decreased more after bariatric surgery than after non-surgical treatment (mean difference −1.5% (−1.9 to −1.1), P<0.001). Heterogeneity was moderate (fig 12⇓).
Medication use was reported by four studies.18 19 24 25 In Schauer 201218 the goal of medical management was to reach an HbA1c ≤6%, a blood pressure of ≤130/80 mm Hg, and a low density lipoprotein cholesterol level of<2.6 mmol/L. In Dixon 200825 drug treatment was determined by an experienced diabetologist on an individual basis. In Liang 201324 the aim was to reach an HbA1c <7% and a blood pressure of ≤140/90 mm Hg. In Ikramuddin 201319 the aim was to reach an HbA1c <7%, low density lipoprotein cholesterol level<2.6 mmol/L, and a systolic blood pressure of ≤130 mm Hg.
Ikramuddin 2013 reported the average change in antidiabetic, antihypertensive, and lipid lowering drug use combined. The group treated by Roux-en-Y gastric bypass used 3.0 (95% confidence interval 2.3 to 3.6) fewer drugs than the non-surgical treatment group at one year of follow-up.19 Schauer 2012 reported that the number of patients receiving antidiabetic drugs decreased from 42 to 10 after Roux-en-Y gastric bypass (−76%) and from 41 to 19 after sleeve gastrectomy (−54%), but did not change after non-surgical treatment at one year of follow-up.18 Liang 2013 reported that oral hypoglycaemic agents and insulin use were stopped in all patients after Roux-en-Y gastric bypass.24 Similarly, Dixon 2008 reported that the number of patients receiving antidiabetic drugs decreased from 28 to three after adjustable gastric banding (−89%) and from 26 to 18 after non-surgical treatment (−18%) at two years of follow-up.25
Schauer 2012 reported, that the number of patients receiving antihypertensive drugs decreased from 39 to 16 after Roux-en-Y gastric bypass (−59%), from 33 to 13 after sleeve gastrectomy (−61%), and from 31 to 30 (−3%) after non-surgical treatment.18 Similarly, Liang 2013 reported that antihypertensive drug use decreased after Roux-en-Y gastric bypass and remained unchanged after non-surgical treatment.24 In Dixon 2008, the number of patients receiving antihypertensive drugs decreased from 20 to six after adjustable gastric banding (−70%) but not after non-surgical treatment.25
Schauer 2012 reported that the number of patients receiving lipid lowering agents decreased from 43 to 13 after Roux-en-Y gastric bypass (−70%) and from 38 to 19 after sleeve gastrectomy (−50%), but increased from 34 to 36 after non-surgical treatment (6%).18 Patients receiving lipid lowering agents after adjustable gastric banding decreased from 12 to four (−67%) and from eight to seven after non-surgical treatment (−13%).25
Quality of life
Quality of life was reported in three studies. Two studies used the SF-36 (Medical Outcomes Trust Short Form 36) questionnaire. In one of these studies,22 three of eight domains (physical role, general health, and vitality) improved more after bariatric surgery, as did five of eight domains in the other study (physical function, physical role, general health, energy, and emotional role).23 In the third study,21 which included adolescents, the Child Health Questionnaire was used. Here, two of eight domains (general health and change in health) improved more after bariatric surgery.
Adverse events are listed in appendix table 9. All but one study17 reported adverse events in the publication, but the missing data were obtained on request. There were no perioperative deaths, cardiovascular events, or deaths during follow-up. One Roux-en-Y gastric bypass patient who developed a leak from the jejuno-jejunostomy suffered anoxic brain injury, lower extremity amputation, and long term disability. After bariatric surgery, 21/261 (8%) individuals required reoperations (15/124 after adjustable gastric banding, 4/69 after Roux-en-Y gastric bypass, 1/49 after sleeve gastrectomy, 1/19 after biliopancreatic diversion). Three individuals developed hernia (1 after Roux-en-Y gastric bypass, 1 after biliopancreatic diversion, 1 after adjustable gastric banding) and five developed pneumonia (2 Roux-en-Y gastric bypass, 3 adjustable gastric banding). Other adverse events occurred after bariatric surgery as well as after non-surgical treatment: 29/194 (15%) developed iron deficiency anaemia after bariatric surgery other than adjustable gastric banding (21/126 Roux-en-Y gastric bypass, 6/49 sleeve gastrectomy, 2/19 biliopancreatic diversion) and 3/169 (2%) after non-surgical treatment. Cholecystitis requiring cholecystectomy occurred in 4/261 (1.5%) of surgically and in 5/169 (3%) of non-surgically treated individuals. Depression developed in 1/261 of surgically treated and in 1/55 of non-surgically treated individuals.
This systematic review and meta-analysis demonstrates that bariatric surgery is more efficient than non-surgical treatment for obesity for up to two years of follow-up. Bariatric surgery led to greater body weight loss, higher rates of remission of type 2 diabetes and metabolic syndrome, greater improvements in quality of life, and greater reductions in use of antidiabetic, antihypertensive, and lipid lowering drugs. Furthermore, waist circumference and fasting levels of plasma glucose, HbA1c, and triglycerides decreased more, and high density lipoprotein cholesterol levels increased more, after bariatric surgery. There was no significant difference between bariatric surgery and non-surgical treatment for changes in blood pressure and levels of total or low density lipoprotein cholesterol (though some studies reported concomitant reductions in drug use for these conditions). There were no perioperative deaths or cardiovascular events reported during follow-up. The most common adverse events after bariatric surgery were iron deficiency anaemia for individuals undergoing malabsorptive bariatric surgery (15%) and reoperations (8%).
Strengths and limitations of study
The strength of this study is its comprehensive approach to identify all randomised controlled trials comparing bariatric surgery with non-surgical treatment for obesity. It quantitatively summarises the currently available evidence on a large spectrum of health outcomes. Our results proved to be robust across various sensitivity analyses and across most subgroups.
We conducted two analyses for remission rates of type 2 diabetes and metabolic syndrome: a complete case and a conservative case scenario. Both types of analysis favoured bariatric surgery over non-surgical treatment concerning remission of type 2 diabetes, but the assumptions made about missing data affected the effect size substantially. Concerning metabolic syndrome remission, only the complete case analysis favoured bariatric surgery.
Though the differences in body weight loss might explain some of the greater improvements in diabetes remission after bariatric surgery compared with non-surgical treatment, changes in the gastrointestinal anatomy, gut hormones, and regulatory factors of energy homeostasis may be the primary mediators.29 30 This is consistent with the findings that Roux-en-Y gastric bypass and biliopancreatic diversion caused diabetes remission within days to weeks after surgery, before substantial weight loss occurred.31 32 Whether different definitions used for type 2 diabetes remission (appendix table 4) had an effect was not investigated because of the limited number of studies identified. However, investigators of future trials are encouraged to use a standard definition for diabetes remission.33
Our study has several limitations. Summary measures of effect sizes are based on only 11 studies or fewer depending on outcome. Furthermore, the methodological quality of five of these studies suffered from unclear allocation concealment. The risk for attrition bias was high in four studies, and attrition was always higher in the non-surgical treatment group. Under the assumption that patients in the non-surgical treatment group with complete data did better than those with missing data, our results seem to represent a conservative estimate of the benefits of bariatric surgery over non-surgical treatment. As far as body weight loss is concerned, the non-surgical treatment group might have been prone to do worse, because it can be assumed that previous weight loss attempts by similar means (such as food restriction) occurred in participants of all studies. Three of the included trials21 22 23 explicitly mentioned that all included individuals were required to have made serious attempts to lose weight before entering the study. Thus, the results presented in our meta-analysis may not apply to individuals without prior weight loss attempts.
All included trials were relatively small, conducted in centres of excellence for bariatric surgery, and limited to a maximum of two years of follow-up. Thus adverse events reported in this meta-analysis may underestimate rates in less specialised centres or in larger trials with broader patient populations, and no conclusions can be drawn for adverse events in the longer term. In addition, it may underestimate rates in obese patients with multiple or severe comorbidities, because such patients were excluded in most of the included trials. It must also be kept in mind that individuals after bariatric surgery must adhere to lifelong micronutrient supplementation after malabsorptive bariatric surgery and are often advised to avoid commonly used drugs such as non-steroidal anti-inflammatory drugs. Furthermore, harms are often poorly reported in surgical trials and randomised controlled trials in general.34 35 In a meta-analysis including 14 studies (1 randomised controlled trial and 13 prospective studies) comparing Roux-en-Y gastric bypass with adjustable gastric banding, perioperative mortality was less than 0.5% for both procedures.36 Reported long term reoperation rates (16% after Roux-en-Y gastric bypass and 24% after adjustable gastric banding) were two to three times higher than in our meta-analysis. In the observational SOS study,37 perioperative mortality for vertical banded gastroplasty, gastric banding, or gastric bypass was 0.25% and reoperation rate was 3%.37
We do not have information from randomised controlled trials on body weight in the longer term. Large prospective observational studies showed that individuals regained about 7% of their lost body weight between two and 10 years after Roux-en-Y gastric bypass.37 38 In contrast, regain of lost body weight in a large trial using lifestyle modification was about 40% between one and four years of follow-up.39
Our meta-analysis could also not investigate the effect of bariatric surgery on cardiovascular morbidity and mortality. A meta-analysis including eight non-randomised trials with 44 022 participants and a mean follow-up of 7.5 years showed a reduction in cardiovascular mortality (odds ratio 0.58 (95% confidence interval 0.46 to 0.73)) and overall mortality (odds ratio 0.7 (0.59 to 0.84)) after bariatric surgery compared with non-surgical controls.40 Thus, the greater improvements in cardiovascular risk factors after bariatric surgery may translate to reduced cardiovascular morbidity and mortality.
We think that, for some meta-analyses, I2 was misleadingly high. Conceptually, I2 represents the ratio of the variability between studies to the variability within studies and is independent from the number of included studies. When the variability within studies is small—represented by narrow confidence intervals—the variability between studies can also be small and the I2 nevertheless high and inflated.41 42 This is shown vividly, for example, by the weight outcome (fig 2⇑). Here, the intuitive, and correct, interpretation of the results is that they consistently show a large effect. The high I2 reflects the uncertainty that remains between the lowest weight loss (∼21 kg) and the largest (∼31 kg), but the results leave us confident that the true effect lies between these values, and the pooled effect (∼26 kg) provides the best single estimate.
In subgroup analyses comparing adjustable gastric banding with other bariatric surgery techniques (Roux-en-Y gastric bypass, sleeve gastrectomy, and biliopancreatic diversion combined) or with Roux-en-Y gastric bypass, there was no significant difference in body weight loss. However, the power of our subgroup analysis to detect differences between adjustable gastric banding and other bariatric surgery techniques was limited by the small number of participants. Furthermore, comparisons are limited to between-study comparisons. In a recent meta-analysis including five randomised controlled trials comparing adjustable gastric banding directly with other bariatric surgery techniques, adjustable gastric banding was associated with less body weight loss.43
The results of this meta-analysis apply to a general population of obese individuals below the age of 60 years with a body mass index ≥30. In the included studies, the age ranged from 16 to 60 years, the proportion of females ranged from 0 to 88%, and the body mass index at baseline from 30 to ≥55 (except for two studies18 24). No information was available on ethnicities, except for one study.19 Results might be different for specific subgroups. The limited number of studies prevented investigations of differential effects due to age or sex. When studies were stratified by mean baseline body mass index, individuals in trials with a body mass index ≥40 lost more body weight after bariatric surgery than individuals in trials with a body mass index <40.
Comparison with other studies
To our knowledge this is the first meta-analysis of randomised controlled trials directly comparing bariatric surgery with non-surgical treatment for obesity. Our results are supported by two systematic reviews. A Cochrane review from 2009 included three randomised controlled trials and three prospective cohort studies. It showed greater body weight loss and greater improvements in cardiovascular risk factors and quality of life after bariatric surgery compared with non-surgical treatment.11 The other systematic review from 2013 included three randomised controlled trials and two prospective cohort studies and had similar results.44 Neither review performed a meta-analysis. A network meta-analysis from 2011 pooled changes in body mass index but did not pool changes in body weight.12 Unlike our meta-analysis, greater improvements in other health outcomes after bariatric surgery were not found. This may be because the network analysis was based on only one direct comparison of bariatric surgery (biliopancreatic diversion) with non-surgical treatment.12
This meta-analysis provides comprehensive evidence that, compared with non-surgical treatment of obesity, bariatric surgery leads to greater body weight loss and higher remission rates of type 2 diabetes and metabolic syndrome. The most common adverse events after bariatric surgery were iron deficiency anaemia (malabsorptive bariatric surgery) and reoperations. Only few studies reported on quality of life, which suggested greater improvements in surgically treated individuals. Results are limited to two years’ follow-up and based on a small number of studies and individuals. The evidence beyond two years of follow-up, in particular on adverse events, cardiovascular diseases, and mortality remains unclear and calls for further research on the topic.
What is already known on this topic
Numerous observational studies and few randomised controlled trials have compared bariatric surgery with non-surgical treatment for obesity
Individual randomised controlled trials were not powered to detect differences in the effects on multiple health outcomes, and no meta-analysis of randomised controlled trials directly comparing the effects of bariatric surgery versus non-surgical treatment for obesity is available
What this study adds
This meta-analysis of randomised controlled trials provides summary effect estimates comparing bariatric surgery with non-surgical treatment for obesity on many different health outcomes
Bariatric surgery is more effective in inducing body weight loss and remission of type 2 diabetes and metabolic syndrome. There were no perioperative deaths or cardiovascular events reported after bariatric surgery. The most common adverse events after bariatric surgery were iron deficiency anaemia (15%) and reoperations (8%)
The lack of evidence beyond two years’ follow-up, in particular on adverse events, cardiovascular diseases, and mortality calls for further research
Cite this as: BMJ 2013;347:f5934
We thank Juliane Schäfer (Institute for Clinical Epidemiology and Biostatistics Basel) for statistical advice; We thank Gordon Guyatt and Diane Heels-Ansdell (Mc Master University, Hamilton, Canada) for comments concerning the statistical heterogeneity observed for some outcomes in this study; and Leonardo Oliveira Reis (Department of Urology, University of Campinas, Sao Paulo, Brazil) and Sayeed Ikramuddin (Department of Surgery, University of Minneapolis) for providing additional outcome data.
Contributors: VLG contributed to the design, did the literature search, checked studies for eligibility, extracted data, did the meta-analysis, and wrote up the manuscript and acts as guarantor. MB gave methodological advice, helped interpret the results, and critically revised the manuscript. DLB, SRK, PRS, and GM were investigators on included trials, provided data for their respective trials, and critically revised the manuscript. HCB critically revised the manuscript. AJN designed the study, checked studies for eligibility, extracted data, wrote up the manuscript, and acts as guarantor. All authors approved the manuscript.
Funding: No specific funding, the Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, is funded by an unrestricted grant from Santéuisse and the Gottfried and Julia Bangerter-Rhyner-Foundation.
The study sponsors did not have any role in the study design, analysis or interpretation of data, in writing of the report or in the decision to submit the article for publication. The researchers were independent from funders.
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: VLG, AJN, MB, and HCB are supported by an unrestricted grant from Santéuisse and the Gottfried and Julia Bangerter-Rhyner-Foundation. DLB is on the advisory boards of Elsevier PracticeUpdate Cardiology, Medscape Cardiology, and Regado Biosciences; is on the boards of directors of Boston VA Research Institute and Society of Cardiovascular Patient Care; is chair of American Heart Association Get With The Guidelines Steering Committee; has received honoraria from American College of Cardiology (editor, Clinical Trials, Cardiosource), Belvoir Publications (editor in chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Population Health Research Institute (clinical trial steering committee), Slack Publications (chief medical editor, Cardiology Today’s Intervention), WebMD (CME steering committees); is senior associate editor, Journal of Invasive Cardiology; is on data monitoring committees of Duke Clinical Research Institute, Mayo Clinic, and Population Health Research Institute; has received research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, the Medicines Company; and has undertaken unfunded research for FlowCo, PLx Pharma, Takeda. PRS has received payment for board membership from Ethicon Endo-Surgery, Surgiquest, Barosense, RemedyMD, and Stryker; consulting fees from Ethicon Endo-Surgery, Stryker, Gore, and Carefusion; payment for expert testimony from Physicians Review of Surgery; lecture fees from Ethi con Endo-Surgery, Allergan, Cinemed, and Quadrant Healthcom; holds a patent for a medical device to enhance weight loss in codevelopment with the Cleveland Clinic; receives royalties from Springer; has an equity interest in Intuitive Surgical, Barosense, Surgiquest, and RemedyMD; and receives institutional grant support (to the Cleveland Clinic) from Ethicon Endo-Surgery and Bard Davol.
Ethical approval: Not required.
Declaration of transparency: The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have been explained.
Data sharing: No additional data available.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.